Skip to content

Earnings call

Indoco Remedies Q1 FY27 earnings call: Indoco expects to have better EBITDA numbers in the next 3 quarters

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Indoco expects to have better EBITDA numbers in the next 3 quarters. Indoco's stand-alone operational revenue grew by 5.8% year-on-year to INR4,081 million in Q1 FY27, while Indoco's consolidated revenue reached INR4,662 million, up by 8.2% year-on-year in Q1 FY27. As per the IQVIA MAT June '26 data, Indoco ranked 33rd in the Indian pharma market. Indoco's overall debt was around INR930 crores as of Q1 FY27, compared with INR964 crores as of March '26; Indoco repaid certain term loans, and the figures combine long-term and short-term debt.

The numbers management gave

Results

  • Indoco's stand-alone operational revenue grew by 5.8% year-on-year to INR4,081 million in Q1 FY27, while Indoco's consolidated revenue reached INR4,662 million, up by 8.2% year-on-year in Q1 FY27.
    Show source
    During Q1 FY27, our stand-alone operational revenue grew by 5.8% year-on-year to INR4,081 million, with consolidated revenue reaching INR4,662 million, up by 8.2% year-on-year.
  • Indoco's stand-alone EBITDA was INR422 million, with an EBITDA margin of 10.3% in Q1 FY27.
    Show source
    Stand- alone EBITDA saw expansion to INR422 million, delivering an EBITDA margin of 10.3%.
  • Indoco's domestic formulations business recorded revenues of INR2,040 million in Q1 FY27.
    Show source
    Our domestic formulations business recorded revenues of INR2,040 million in quarter 1 FY27.
  • International formulations contributed 35% of Indoco's revenue in Q1 FY27, at INR1,451 million.
    Show source
    International formulations contributed 35% of the quarter 1 FY27 revenue at INR1,451 million, while our active pharmaceuticals business delivered a stellar performance this quarter, surging to 42% Y-o-Y and a turnover of INR522 million.
  • Indoco's active pharmaceuticals business grew 42% year-on-year and had a turnover of INR522 million in Q1 FY27.
    Show source
    International formulations contributed 35% of the quarter 1 FY27 revenue at INR1,451 million, while our active pharmaceuticals business delivered a stellar performance this quarter, surging to 42% Y-o-Y and a turnover of INR522 million.
  • Indoco's cost of goods went up almost 2 percentage points in Q1 FY27 because of the war situation and shortages in the availability of materials, as well as increased pricing.
    Show source
    So for this particular quarter, you see COGS impacted and almost by 2 percentage points, our cost of goods has gone up.
Show 20 more statements

Results

  • Following the hiving off of Indoco's ophthalmic division, the cost of 200 people engaged in that activity came down for 1, 1.5 months this quarter.
    Show source
    In addition to that, with the hiving off of the ophthal division, 200 people engaged in that activity, their cost also for 1, 1.5 months this quarter has come down.
  • Consolidated advertisement and sales promotion was approximately INR30-plus crores in Q1 FY27.
    Show source
    So approximately in quarter 1 at consol level, we have about INR30-plus crores of advertisement and sales promotion.
  • New introductions are contributing close to INR100 crores at a MAT level.
    Show source
    But otherwise also, there is a lot of -- if you looked at our new product performance, close to INR100 crores is now coming on a MAT level from new introductions.
  • Consolidated other expenses were below INR150 crores in Q1 FY27.
    Show source
    Pramod Ghorpade: Below INR150 crores at consol level.
  • Warren Remedies' OTC business delivered a top line of INR34 crores in Q1 FY27, with healthy growth.
    Show source
    So for the first quarter this year, the OTC business of Warren Remedies has delivered a top line of INR34 crores with a healthy growth.
  • Returns on Sensodent-K and Sensodent KF are gradually improving.
    Show source
    On Sensodent-K, Sensodent KF also, gradually, we are able to get better returns.
  • The U.S. subsidiary was positive in Q1 FY27. Replaced by a later filing.
    Show source
    Pramod Ghorpade: This quarter, it is positive.

Money and capital

  • Indoco's overall debt was around INR930 crores as of Q1 FY27, compared with INR964 crores as of March '26; Indoco repaid certain term loans, and the figures combine long-term and short-term debt.
    Show source
    So, overall debt level remains at around INR930 crores now as against INR964 crores as of March '26.
  • Indoco's overall interest cost is in the range of 9%.
    Show source
    While the interest cost, as we discussed last time also, it is in the range of 9% overall, which is quite competitive at this point of time.
  • Indoco's long-term debt was INR600 crores at June end.
    Show source
    Our debt level, long-term debt is at currently INR600 crores.
  • Indoco had about INR100 crores plus of repayment scheduled from July to March this particular year.
    Show source
    We have another about INR100 crores plus repayment schedule, which is for this partic ular year, July to March.
  • Indoco's short-term debt was in the range of INR325 crores at June end.
    Show source
    And short term is in the range of INR325 crores.
  • Indoco's total debt was around INR930 crores at June end.
    Show source
    So both put together, we are at around INR930 Page 9 of 18 Indoco Remedies Limited July 28, 2026 crores at this June end.
  • Indoco's objective is to repay INR110 crores this year and another INR150 crores in next year, for around INR260 crores in repayments within about 7 to 18 months.
    Show source
    Our objective is to repay INR110 crores this year and another INR150 crores in next year.
  • Indoco's short-term debt can be less than INR300 crores or INR320 crores, INR330 crores, depending on the collection cycle.
    Show source
    Sometimes it will be INR320 crores, INR330 crores kind of short-term cycle.
  • Indoco's finance cost is about 9% on an average of INR900 crores, or roughly INR81 crores.
    Show source
    So, purely finance cost 9% on an average of INR900 crores, you can see roughly about INR81 crores.
  • Indoco's quarterly finance cost is around INR20 crores.
    Show source
    If I split between a quarterly, it is around INR20 crores.
  • Indoco's average interest cost is about INR20.5 crores on overall debt.
    Show source
    So, that is the -- average interest cost is about INR20.5 crores on an overall debt.
  • Indoco's finance cost includes certain exchange losses.
    Show source
    Secondly, certain exchange losses are also factored as part of finance cost.
  • Part of the INR140 crores debt repayment will be funded from the proceeds, but not all of the proceeds will be used to pay debt. Replaced by a later filing.
    Show source
    I think what we're trying to say is the INR140 crores repayment that has to be done, part of that will come from some of these proceeds.

What it expects ahead

What management expects

  • Indoco expects to have better EBITDA numbers in the next 3 quarters.
    Show source
    So, this particular year, as you would have seen, ou r EBITDA number and probably we'll have better numbers going forward in the next 3 quarters.
  • Management said other expenses of INR110 crores to INR120 crores were a decent level and did not guide to a lower level.
    Show source
    But I think INR110 crores is what we can -- INR110 crores, INR120 crores what we can...
  • Domestic and emerging markets are expected to grow at a CAGR of about 10% to 11% in the next 2 to 3 years.
    Show source
    Domestic and emerging market, you mentioned about good growth, about 10% to 11% kind of CAGR in the next 2 to 3 years.
  • Indoco will leverage its integrated R&D, CRO and API capabilities internationally to accelerate high-value filings in complex ophthalmics, injectables and oral solids.
    Show source
    Internationally, we will leverage our integrated R&D, CRO and API capabilities to accelerate high-value filings in complex ophthalmics, injectables and oral solids.
  • Indoco expects higher single-digit to double-digit growth in its India business going forward.
    Show source
    So, you should expect higher single-digit to double-digit growth in India business going forward.
  • The company will provide guidance on the U.S. market once it gets clarity about USFDA; U.S. market prospects depend on regulatory approval and certain regulatory challenges.
    Show source
    But once we get certain clarity about USFDA, then only we'll be able to give some guidance on U.S. market.
Show 3 more statements

What management expects

  • Indoco expects to sustain profitable growth across all core businesses. Replaced by a later filing.
    Show source
    Looking ahead, I'm confident in our ability to sustain profitable growth across all core businesses.

Orders

  • Indoco has in excess of INR250 crores of orders in hand for execution; lower shipments and bookings for the quarter reflected timing, not a lack of orders.
    Show source
    I think as of now, we have in excess of INR250 crores of orders in hand for execution.
  • The company has been able to supply to Europe as per the order book. Replaced by a later filing.
    Show source
    We have been able to supply as per the order book.

What it is building and selling

Demand and pricing

  • As per the IQVIA MAT June '26 data, Indoco ranked 33rd in the Indian pharma market.
    Show source
    As per the IQVIA MAT June '26 data, Indoco continues to maintain a solid position in the Indian pharma market at the 33rd rank while maintaining an impressive 20th rank MAT May '26 in prescription volume.
  • Indoco maintained a 20th rank in prescription volume as per MAT May '26 data.
    Show source
    As per the IQVIA MAT June '26 data, Indoco continues to maintain a solid position in the Indian pharma market at the 33rd rank while maintaining an impressive 20th rank MAT May '26 in prescription volume.
  • Kidodent performed exceedingly well. Replaced by a later filing.
    Show source
    Some products like Kidodent have done exceedingly well.

Segments

  • The company is investing in new products for its India business and emerging markets. Replaced by a later filing.
    Show source
    So, there is a lot of investment by way of new products, et cetera, for India business as well as in emerging.

Risks, rules and outside factors

Rules and policy

  • Indoco Stability Center, IAS, at Chhatrapati Sambhajinagar, Aurangabad successfully completed a USFDA pre-approval inspection with 0 observation.
    Show source
    I'm happy to share that Indoco Stability Center, IAS, at Chhatrapati Sambhajinagar, Aurangabad successfully completed a pre-approval inspection by the USFDA with 0 observation.
  • Indoco's Baddi Unit I successfully completed a Malta Medicines Authority audit.
    Show source
    On the regulatory approval side, I'm pleased to share that our Baddi Unit I successfully completed Malta Medicines Authority audit, while our Baddi Unit III facility received EU-GMP Page 2 of 18 Indoco Remedies Limited July 28, 2026 certification from the German Health Authority, Berlin.
  • Indoco's Baddi Unit III facility received EU-GMP certification from the German Health Authority, Berlin.
    Show source
    On the regulatory approval side, I'm pleased to share that our Baddi Unit I successfully completed Malta Medicines Authority audit, while our Baddi Unit III facility received EU-GMP Page 2 of 18 Indoco Remedies Limited July 28, 2026 certification from the German Health Authority, Berlin.
  • Indoco's Goa plant I successfully cleared the Malta Medicines Authority audit.
    Show source
    Adding to this, our Goa plant I successfully cleared the Malta Medicines Authority audit.
  • Indoco's Goa plant I has EU-GMP certification from the authority, confirming that it complies with good manufacturing practice requirements referred to in the EC Directive.
    Show source
    The facility has EU-GMP certification from the authority, confirming that it complies with the good manufacturing practice requirements as referred in the EC Directive.

Everything else said on the call

What management stressed

  • Indoco's India priorities are scaling midsized brands into mega brands, deepening specialty prescription share and expanding its chronic footprint.
    Show source
    In India, our priorities are scaling midsized brands into mega brands, deepening specialty prescription share and expanding our chronic footprint.
  • Indoco is consistently looking at bringing down employee costs and reducing costs of repairs and maintenance, stores and spares. Replaced by a later filing.
    Show source
    We are consistently looking at reducing cost of repairs and maintenance, stores and spares.

Group structure

  • Indoco's divestment of the Ophthalmic Division in India and agreed territories in Africa is an important step in sharpening its focus on core therapeutic areas with stronger potential.
    Show source
    It is worthwhile to mention that the divestment of the Ophthalmic Division in India and agreed territories in Africa is an important step in sharpening our focus on core therapeutic areas with stronger potential.

Other

  • Overall, the figure was not even INR40 crores to INR50 crores for the whole year. Replaced by a later filing.
    Show source
    Pramod Ghorpade: Not even INR40 crores Aditi Panandikar: Not even INR40 crores to INR50 crores overall for the whole year.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Nirmam Mehta: Okay. Secondly, on our international business, so when we see revenues are largely flat, the U.S. business has grown, but Europe business has not grown and there's a degrowth in the emerging markets. So, are there any concerns? Or do you expect these markets to grow for this year? Page 4 of 18 Indoco Remedies Limited July 28, 2026 Aditi Panandikar: Yes.

    Answer, aditi panandikar

    So, I'll start with the emerging business. So as you know, emerging is a branded formulations market. And sometimes for the March quarter end, there is a bit of a push and especially with the war-like situation and there were shortages of products. So, there was a good amount of primary billing in March. But if you look at the March, April in combined, then we are still doing a much better per month sales. But I'm sure this is only a temporary 1 quarter glitch.

  2. Question

    Nirmam Mehta: Even for the European markets?

    Answer, aditi panandikar

    Aditi Panandikar: Yes. Europe is about roll-in orders. So, probably it is just about -- the timing must have not been able to sort of release products on time, et cetera. I'm sure there is nothing fundamentally wrong.

  3. Question

    Nirmam Mehta: Okay. And on the domestic business, so Indoco stand-alone business plus the warrant, I think even that business has been flat. So, any comments on both of that?

    Answer, aditi panandikar

    Aditi Panandikar: So if you look at the top 10 large brands of the company, then we have got almost all segments in double-digit positive growth, except 2 products, 2 segments. One is anti-infective and the other is respiratory. And both are very seasonal. And this year, we did not get rains in June. So, there was almost a 1-month pushover. So, I expect that is why on a Q1-to-Q1 basis, you see that drop. If you look at performance on the immediate preceding quarter basis, you will see a good growth because the season has started to come in, but it is not equivalent to what it was last year.

    Answer, aditi panandikar

    So sadly, the wonderful performance by all other brands, whether you look at Cital, Carmicide, Cyclopam. You look at some of the other brands, like I think, even your -- all the dentistry products, have all done very well. It is only Febrex Plus, Karvol Plus and one antibiotic, which are heavily degrown on the primary, that too.

  4. Question

    Nirmam Mehta: So, what would be the potential for these brands? I mean, at the India business, can we grow double digits here for next 1, 2 years or these are high single-digit growth brands? How do we look at these?

    Answer, aditi panandikar

    Aditi Panandikar: So as the top 10 brands contribute more and more to total turnover, we are much more in control of delivering a more consistent performance. So, you should expect higher single-digit to double-digit growth in India business going forward.

  5. Question

    Nirmam Mehta: Okay, ma'am. And lastly, on the margins. So while the margins have grown year-on-year, but our gross margins have taken a hit for the quarter. So, do you expect these gross margins....?

    Answer, aditi panandikar

    Aditi Panandikar: Gross margins, this quarter, we had an impact of the increase in cost of goods because of the war situation. And a lot of the products, there were shortages even in availability of materials, let alone the increased pricing. So for this particular quarter, you see COGS impacted and almost by 2 percentage points, our cost of goods has gone up. Otherwise, the performance would have been even better.

  6. Question

    Nirmam Mehta: Sure, ma'am. And lastly, just on the debt and interest cost. So Pramod sir, if you can highlight the debt number and how do we expect the interest cost to pan out for the year?

    Answer, pramod ghorpade

    Pramod Ghorpade: Yes. So overall debt, we have reduced by almost about INR30-odd crores as compared to what we used to have in March '26. So, overall debt level remains at around INR930 crores now as against INR964 crores as of March '26. So, we have repaid certain term loans. This is both put together, long term and short term put together. While the interest cost, as we discussed last time also, it is in the range of 9% overall, which is quite competitive at this point of time.

    Answer, aditi panandikar

    Aditi Panandikar: So European market, as I said already, this was a one -off quarter where there was a dip. But otherwise, we expect very good consistent performance for Europe. And there is a good product basket, very predictable. We supply Europe from our Baddi sites and some also comes from Goa. For U.S., you asked specifically about new laun ches. So as you know, for the sterile business, our new product approvals are held because of the U.S. audit, which is yet to happen. But all the same current products, includ ing brimonidine, dorzolamide, [dorzol/timo 0:18:44], as well as solid orals like allopurinol, glimepiride, vildagliptin are doing exceedingly well.

    Answer, aditi panandikar

    For the solid orals of the future, of course, we have some products, which will be -- we will be able to launch post-patent expiry in '27. There are some early patent expiries expected in Europe next year. We will talk of them as the time approaches.

  7. Question

    Sudarshan Padmanabhan: Do we have any aspiration for, say, FY27, FY28 for European and U.S. business? And specifically with respect to Vigamox, how do we see this product gathering momentum and how big would this product end up being?

    Answer, aditi panandikar

    Aditi Panandikar: So as I said, at this stage, it is better to not say anything about ophthalmics too much. I would wait for the USFDA audit to happen after which we should discuss more concretely numbers.

  8. Question

    Sudarshan Padmanabhan: And with respect to the cash that is coming in primarily post the transaction, one, I mean, what should be the use of it? Because if I look at the domestic business, I mean, as you mentioned, I think the anti-infectives has been a little bit of a joker in the pack, a little bit more volatile than what was expected. So, I mean, would you be primarily looking to repay debt? Or is there a way where you can buy growth in?

    Answer, aditi panandikar

    Aditi Panandikar: So going forward, definitely, the company will look to invest in acquisition of brands possibly for India business. But at this point in our journey, it was more important to repay debt, I think. So, some of this money that is accrued has gone towards that for sure. Page 6 of 18 Indoco Remedies Limited July 28, 2026 Sudarshan Padmanabhan: Yes.

  9. Question

    Sure, ma'am. And with respect to -- one is the operating leverage as the scale picks up, I mean probably the last few quarters is clearly not the right representative of the business trends. So, I mean, where do you see the steady state margins going forward in the next 6 months or the next 2 years?

    Answer, aditi panandikar

    Aditi Panandikar: So, you must have noted we are not giving any definite guidances on margins exactly. But if you have looked at the performance of the company over the last 9 quarters, you will agree the last 2 quarters show a very clear upward trend in improvement in performance, okay, although I agree that international business this quarter has given a bit of a dip. But otherwise, consistently across domestic, international, reg and as well as API, you see a very consistent growth. API division, in particular, has done very well. So, we expect margins to keep improving quarter-on- quarter from here on.

  10. Question

    Sudarshan Padmanabhan: Sure, ma'am. One last question before I join the queue is one is, of course, operating leverage, but do you see any areas where we can reduce the costs, improve the efficiency given that we have seen challenges as far as growth is concerned?

    Answer, aditi panandikar

    Aditi Panandikar: Right. So you must have -- you remember, we must have spoken earlier about our Master Manufacturing Plan, whereby we increased efficiency in the plant, increased batch sizes, looked at reorganizing the product mix across various locations, looked at reducing process time, increasing speed of packing, et cetera. All that now structurally is in place. As the orders start flowing in, this will result into requisite numbers. Even for this first quarter, if I have to tell you, if we look at the number, the value of product made first quarter last year and first quarter this year. And if you look at the number of batches taken, we have actually manufactured 26% less batches. So, that definitely will result in efficiency over a period of time.

    Answer, aditi panandikar

    We have also reduced the number of people engaged in operations because due to the high-speed machines, due to automation, we are able to optimize that. And all of this eventually will slowly start showing in the margin. Does that answer your question?

Show 14 more questions
  1. Question

    Kenil Mehta: Ma'am, just wanted to know any particular reason why we haven't scaled up our emerging market and European business because over last few quarters, we were very bullish?

    Answer, aditi panandikar

    Aditi Panandikar: Yes. So like I -- yes, Kenil sir, like I answered earlier, emerging business is a branded business. Also to Africa emerging business when it is sold is like booking primaries. I just look quickly at the secondary growth in the emerging business quarter-on-quarter. They're extremely steady, good double-digit growth in secondary demand. So, this kind of fluctuation you see over the March quarter and then the first quarter next year. Of course, there were challenges of product availability because of war issues.

    Answer, aditi panandikar

    There were some challenges related to being able to get the right freight at the right cost. Those things were there, but they have not impacted much. Page 7 of 18 Indoco Remedies Limited July 28, 2026 The real impact is that after the very high range because emerging was on 110% to 101% last year. So, you expect a little bit of that and then the first quarter does take an impact. So to that extent, there has been a bit of an impact from emerging, but I don't -- fundamentally, secondaries are doing really well. And I, therefore, expect primaries to rebound immediately as in second quarter. Coming to Europe, again, international business reg did a record -breaking number for the March quarter.

    Answer, aditi panandikar

    And for this quarter, looking at the rolling plans from some of our European customers, it is just 1 quarter where we've not been able to ship a lot and therefore, not booked it . But I don't expect this to be a very big problem. I think as of now, we have in excess of INR250 crores of orders in hand for execution. So, this is not on account of not having orders. It is probably just the timing of it.

  2. Question

    Kenil Mehta: Okay. And this order book is for 3 to 6 months or for 1 year?

    Answer, aditi panandikar

    Aditi Panandikar: So that is the thing. Most of our buyers and partners, we've been in partnership for a very long time. And I think some of my boys when they do their KRAs, work it out, so they push a bit here, push a bit there. What I'm trying to tell you is that the order book position is really very good and fundamentally, there will be good growth, not to worry.

  3. Question

    Kenil Mehta: Understood. And does that include all the new products also?

    Answer, aditi panandikar

    Aditi Panandikar: Okay. So, I think Goa plant I right now on a single shift basis is occupied to 80% roughly. 70% to 80%. And Baddi I, which is a smaller capacity, high -value kind of plant i s also occupied to the range of 70% to 80% on a single shift that too. Baddi III, which is the large plant which makes paracetamol, again, in the range of 70%, 75%, if I'm not mistaken.

  4. Question

    Kenil Mehta: Okay. So, all the incremental as we expand our quarterly exports to INR200 crores mark will lead to higher efficiency and margin expansion?

    Answer, aditi panandikar

    Aditi Panandikar: Yes, yes. So this is -- this quarter inability to supply has not resulted in the top line. And as you correctly said, as these capacities get further utilized, you will start seeing the efficiency.

  5. Question

    Kenil Mehta: Understood. So going forward, do you think in this financial year, we will see a PAT -- profitability for a quarter going forward in coming quarters?

    Answer, aditi panandikar

    Aditi Panandikar: That's what we are working for. Page 8 of 18 Indoco Remedies Limited July 28, 2026 Kenil Mehta: Understood.

  6. Question

    And ma'am, can you -- just a suggestion -- can you give the paper burn PPT, [inaudible 0:27:37] FPP? What is the revenue of FPP and profitability and warrant separately so we can get to know where the hanging fruit is because if FPP is getting profitable during this quarter, then the warrant should also improve the numbers going forward? So, we can get to know the consolidated numbers in a simple manner and where the issue is?

    Answer, aditi panandikar

    Aditi Panandikar: Yes. So if you look at our business, there are 3 main segments really. One is the India business, which is the most profitable, obviously. Emerging follows very close, almost same levels. So these businesses, there is nothing to worry about how profitable they are or whether they return cash and things like that. So as these businesses grow fast, of course, this will come into operating profits. The international business, especially the one to Europe is now of quite a substantial size.

    Answer, aditi panandikar

    And given the kind of investments we have already made in improving efficiency at the plant, this business on the high number, when profitability of this business improves, it will also come down into operating profit. U.S., on the other hand, is right now in a high -growth phase, meaning it's very small, and we will continue to sell more. And while this U.S. business at a GC level is very profitable, U.S. has its own challenges on working capital cycles, et cetera. But it will add, but it will not dent too much. So as per me, from a scaling of operating profit angle, one should look at India and emerging steadily adding to it and one should expect increased profit coming from Europe. Kaustav Bubna: Okay. And what about your debt levels?

    Answer, pramod ghorpade

    Pramod Ghorpade: Yes, Kaustav. Our debt level, long-term debt is at currently INR600 crores. We have another about INR100 crores plus repayment schedule, which is for this partic ular year, July to March. And short term is in the range of INR325 crores. So both put together, we are at around INR930 Page 9 of 18 Indoco Remedies Limited July 28, 2026 crores at this June end. And we are repaying our -- as per our repayment schedule. So, this particular year, as you would have seen, ou r EBITDA number and probably we'll have better numbers going forward in the next 3 quarters.

    Answer, pramod ghorpade

    We'll be able to repay the principal as well as interest component for remaining 3 quarters.

  7. Question

    Kaustav Bubna: So what -- is it realistic to talk about INR500 crores long-term plus short-term debt together in a few years or that's too ambitious?

    Answer, pramod ghorpade

    Pramod Ghorpade: Yes. Certainly, certainly. Our objective is to repay INR110 crores this year and another INR150 crores in next year. So, around INR260 crores, we are going to repay within next about 7 to 18 months.

    Answer, aditi panandikar

    Aditi Panandikar: Yes. So yes, thank you for that. This is something we have been working on for a very long time. As you know, the company employs close to 6,000 people and half of them are in field as sales and good 40% are employed across various manufacturing sites in particular. And here, we have seen maximum efficiency. As I mentioned earlier, 26% less number of batches have been taken to get equivalent or more sales for international business this year. Consequently, we've been able to bring down the number of people engaged in operations by quite a large number.

    Answer, aditi panandikar

    Quite honestly, close to 900 people have been reduced. In addition to that, with the hiving off of the ophthal division, 200 people engaged in that activity, their cost also for 1, 1.5 months this quarter has come down. So, we are consistently looking at bringing down employee costs. We are consistently looking at reducing cost of repairs and maintenance, stores and spares. There is a very deep planning involved in operational efficiency to the extent that if we have to run one shift, we run only shift, nothing more. So keeping utilities in check, looking at unnecessary expenditure, which can be postponed. So, a lot of work going on, and I think you're able to see that.

  8. Question

    Pratik Kothari: If you can just highlight where is this?

    Answer, pramod ghorpade

    Pramod Ghorpade: Yes. Pratik, there are 2 components. One is term loan and second is working capital, the short- term component. So short term, INR320 crores, as I said, it depends on the cycle of collection. In case of domestic, as you know, we have 7 plus 21 days of kind of a collection cycle. While Page 10 of 18 Indoco Remedies Limited July 28, 2026 in case of exports, each market has different terms. So depending on the collection cycle, our short term also varies.

    Answer, pramod ghorpade

    Sometimes it will be less than INR300 crores. Sometimes it will be INR320 crores, INR330 crores kind of short-term cycle. And based on that, interest value in terms of quantum will change. That is one. Secondly, certain exchange losses are also factored as part of finance cost. So, purely finance cost 9% on an average of INR900 crores, you can see roughly about INR81 crores. If I split between a quarterly, it is around INR20 crores.

    Answer, pramod ghorpade

    So, that is the -- average interest cost is about INR20.5 crores on an overall debt.

  9. Question

    Pratik Kothari: One last, sorry. On the debt part, right, so we got INR100-odd crores from Ophthal. And last quarter, we called out the land parcel that we have that we intend to sell. This is over and above the INR140 crores of debt repayment that we intend to do.

    Answer, aditi panandikar

    Aditi Panandikar: So no, no, there is nothing additional. I think what we're trying to say is the INR140 crores repayment that has to be done, part of that will come from some of these proceeds. But all of these proceeds will not be used for paying debt.

  10. Question

    Pratik Kothari: So, this INR100 crores which came from Ophthal, have we utilized that or that's lying on our balance sheet?

    Answer, pramod ghorpade

    Pramod Ghorpade: Got it. So approximately in quarter 1 at consol level, we have about INR30-plus crores of advertisement and sales promotion.

    Answer, aditi panandikar

    Aditi Panandikar: Correct. And on a stand-alone basis also, if you're looking at last 3, 4 years, then post -COVID, naturally, there will be increase because in COVID times, they were completely dampened. But otherwise also, there is a lot of -- if you looked at our new product performance, close to INR100 crores is now coming on a MAT level from new introductions. So, there is a lot of investment by way of new products, et cetera, for India business as well as in emerging.

  11. Question

    Raja Kumar: Okay. That's good. And then the good work that you have done on the other expenses, so do you expect some more work to be done in the upcoming quarters? Or we are -- this number is to be taken a steady state?

    Answer, aditi panandikar

    Aditi Panandikar: There will work -- work will continuously go on, sir, but this number, I think, is decent right now. I wouldn't like to unless guide you to something better than this. But I think INR110 crores is what we can -- INR110 crores, INR120 crores what we can...

    Answer, pramod ghorpade

    Pramod Ghorpade: Below INR150 crores at consol level.

  12. Question

    Dhruv Sitlani: Healthy unit economics today or not?

    Answer, aditi panandikar

    Aditi Panandikar: Healthy. Okay. Yes, yes, yes. So for the first quarter this year, the OTC business of Warren Remedies has delivered a top line of INR34 crores with a healthy growth. And looking at the kind of expenses, you have to understand this is a very competitive sensitivity and general oral care market. Some products like Kidodent have done exceedingly well. On Sensodent-K, Sensodent KF also, gradually, we are able to get better returns.

  13. Question

    Kenil Mehta: No, no. Overall.

    Answer, pramod ghorpade

    Pramod Ghorpade: Not even INR40 crores Aditi Panandikar: Not even INR40 crores to INR50 crores overall for the whole year.

    Answer, sundeep bambolkar

    Sundeep Bambolkar: So we -- see, Mr. Raghu Ram, as madam also explained, we see all 3 businesses in a different way. Domestic and emerging market, you mentioned about good growth, about 10% to 11% kind of CAGR in the next 2 to 3 years. While in case of reg market, Europe is almost settled. We have been able to supply as per the order book. U.S. market, it depends on the regulatory approval, certain regulatory challenges. So, we don't want to comment very much on U.S. market at this point of time. But once we get certain clarity about USFDA, then only we'll be able to give some guidance on U.S. market.

  14. Question

    Kenil Mehta: Understood. Understood. And ma'am, U.S. subsidiary is profitable going forward after the one- off issue has been sorted out of inventory write-off. Is it correct now?

    Answer, pramod ghorpade

    Pramod Ghorpade: This quarter, it is positive.

Questions about this call

When was the Indoco Remedies Q1 FY27 earnings call transcript filed?
Indoco Remedies filed the transcript with the exchange on 4 Aug 2026. This page is built from that transcript.
What does this page list?
48 statements from the transcript across 10 topics, 16 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 24 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Indoco Remedies Q1 FY27 concall: Indoco expects to have better EBITDA numbers in the next 3 quarters · DalalOS